Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: diagnostic and therapeutic implications

Igor Theurl,1 Elmar Aigner,2 Milan Theurl,1,3 Manfred Nairz,1 Markus Seifert,1 Andrea Schröter,1 Thomas Sonnweber,1 Lukas Eberwein,1 Derrick R. Witcher,4 Anthony T. Murphy,4 Victor J. Wroblewski,4 Eva Wurz,1 Christian Datz,2 and Guenter Weiss1

1Department of Internal Medicine I, Clinical Immunology and Infectious Diseases, Medical University of Innsbruck, Innsbruck, Austria; 2Department of Internal Medicine, General Hospital Oberndorf, Oberndorf, Austria; 3Department of Ophthalmology, Medical University of Innsbruck, Innsbruck, Austria; and 4Biotechnology Discovery Research, Lilly Research Laboratories, Indianapolis, IN

The anemia of chronic disease (ACD) is characterized by macrophage iron retention induced by cytokines and the master regulator hepcidin. Hepcidin controls cellular iron efflux on binding to the iron export protein ferroportin. Many patients, however, present with both ACD and iron deficiency anemia (ACD/IDA), the latter resulting from chronic blood loss. We used a rat model of ACD resulting from chronic arthritis and mimicked ACD/IDA by additional phlebotomy to define differing iron-regulatory pathways. Iron retention during inflammation occurs in macrophages and the spleen, but not in the liver. In rats and humans with ACD, serum hepcidin concentrations are elevated, which is paralleled by reduced duodenal and macrophage expression of ferroportin. Individuals with ACD/IDA have significantly lower hepcidin levels than ACD subjects, and ACD/IDA persons, in contrast to ACD subjects, were able to absorb dietary iron from the gut and to mobilize iron from macrophages. Circulating hepcidin levels affect iron traffic in ACD and ACD/IDA and are more responsive to the erythropoietic demands for iron than to inflammation. Hepcidin determination may aid to differentiate between ACD and ACD/IDA and in selecting appropriate therapy for these patients. (Blood. 2009;113:5277-5286)

Introduction

The anemia of chronic disease (ACD), also termed the “anemia of inflammation,” is the most prevalent anemia in hospitalized patients.1,2 ACD develops in subjects with diseases involving acute or chronic immune activation, such as patients with infections, malignancies, or autoimmune disorders. At least 3 major immunity-driven mechanisms contribute to the anemia of ACD.

First, the retention of iron within the mononuclear phagocytic system leads to hypoferremia and subnormal saturation of transferrin, resulting in a limited availability of iron for erythroid progenitor cells or “functional iron deficiency.”3,4 Second, cytokines, such as tumor necrosis factor-α, interferon-γ, and interleukin-1 (IL-1), exert a negative impact on the proliferation and differentiation of erythroid progenitor cells and can induce apoptosis.5 Third, patients with ACD display an impaired response to erythropoietin (EPO).6

The functional iron deficiency present in patients with ACD can be complicated by true iron deficiency resulting from chronic blood loss.7 Differentiation between ACD and ACD/iron deficiency anemia (IDA) is clinically important because iron supplementation is beneficial for ACD/IDA patients but may be deleterious for ACD patients, especially if these subjects have underlying infections or malignancies.1 In clinical practice, however, differentiating between ACD and ACD/IDA is difficult, as both diseases present with decreased serum iron concentration and transferrin saturation. In addition, ferritin levels are difficult to interpret during inflammation because ferritin expression is induced by both iron overload and inflammatory cytokines.8 A ratio of soluble transferrin receptor (sTfR)/log ferritin may be useful in distinguishing ACD from ACD/IDA, but the ratio has not been widely used in clinical practice.9 New markers, which accurately indicate the need for iron for erythropoiesis without requiring bone marrow aspiration, are clearly needed.

The liver-derived acute phase protein hepcidin is the master regulator of iron homeostasis. Hepcidin expression is induced by both iron overload and inflammatory stimuli.10,11 Hepcidin binds to ferroportin, the only known iron export protein, resulting in the internalization and degradation of this transporter, which then blocks iron export from enterocytes and macrophages to the circulation.12-14 Cytokine-inducible synthesis of hepcidin plays a critical role in macrophage iron retention, which underlies ACD.15,16 However, information on circulating concentrations of hepcidin in patients with ACD and ACD/IDA is sparse, and a correlation between hepcidin and iron availability in the setting of inflammation has not yet been reported. This has been because of the lack of a widely available method for measuring hepcidin in plasma. Mass spectroscopy has been reported in small series, and the first enzyme-linked immunosorbent assay (ELISA) method for determining hepcidin was recently published.17

In addition, few suitable animal models of ACD have been available, although several mouse models have been used to study hypoferremia.10 Most of the murine models display a mild anemia and hypoferremia after injection of inflammatory stimuli, but the hypoferremia normalizes within 24 to 72 hours.18
Here, we report a rat model in which arthritis was induced on intraperitoneal administration of peptidoglycan-polysaccharide-fragments (PG-APS). Arthritic rats develop a long-lasting anemia with the features of ACD. We used this animal model to study differences in the regulation of iron homeostasis between ACD, IDA, and ACD/IDA, the utility of serum hepcidin levels to discriminate between these different entities, and to study therapeutic iron replenition strategies. Data obtained in the rodent model were compared with data from patients with ACD, IDA, or a combination of both.

**Methods**

**Patients**

Blood samples were obtained by venipuncture from 67 patients with ACD, IDA, or age-matched controls. The study was approved by the local ethics committee at the Medical University of Innsbruck (approval no. UN3256 and approval no. UN3468). In addition, some patients with ACD and/or IDA underwent gastroduodenoscopy for clinical purposes at the Department of Internal Medicine, Oberndorf Hospital (Salzburg, Austria). Written informed consent was obtained in accordance with the Declaration of Helsinki from these patients to permit duodenal biopsies during routine gastroduodenoscopy for scientific purposes.

Patients were considered to have ACD when (1) they had a chronic infection or autoimmune disease, (2) they were anemic with a hemoglobin of less than 13 g/dL for men and less than 12 g/dL for women, and (3) they had low transferrin saturation (TfS < 16%), but normal or increased serum ferritin concentrations (> 100 ng/mL) or low serum ferritin concentrations (30-100 ng/mL) and a sTfR/log ferritin ratio less than 1.1,9

In contrast, patients were considered to have ACD with true iron deficiency (ACD/IDA) when (1) they had a chronic infection, autoimmune disease, or malignancy; (2) they were anemic with a hemoglobin of less than 13 g/dL for men and less than 12 g/dL for women; and (3) they had a TfS less than 16%, a serum ferritin concentrations less than 100 ng/mL, and a sTfR/log ferritin ratio more than 2.9

Among the 15 patients with ACD, 7 had bacterial pneumonia with 2 of them developing empyema, 3 suffered from recurrent urinary tract infection, 1 from rheumatoid arthritis, 1 from infectious colitis, 1 from systemic lupus erythematosus, and 1 from osteomyelitis. Among the 14 patients with ACD and true iron deficiency, 4 had bacterial pneumonia, 3 suffered from rheumatoid arthritis, 2 from systemic lupus erythematosus, 1 from systemic sclerosis, 1 from chronic pancreatitis, 1 from chronic cholecystitis, and 2 from recurrent urinary tract infections. Although some patients received antibiotics at enrollment, none of the patients with newly diagnosed autoimmune disorders had been treated with immunosuppressive drugs before study enrollment.

We also studied a group of age-matched controls (n = 26) with no signs of anemia, normal serum iron status, and no signs of inflammation (normal serum concentrations of C-reactive protein; < 1 mg/dL) and 12 patients with IDA with low hemoglobin (men < 13 g/dL and women 12 < g/dL), TfS (< 16%), and ferritin concentrations (< 30 ng/mL) but no signs of inflammation.

None of our patients received treatment with iron, blood transfusions, or recombinant human erythropoietin before study entry. Blood samples were drawn on a routine basis, and laboratory parameters, for example, hemoglobin, red blood cell count, and serum iron parameters were determined by routine automated laboratory tests.

Serum specimens were drawn during this routine examination and stored at ~80°C until cytokine assays were performed. Determination of serum IL-6 concentrations was carried out using a commercially available ELISA kit obtained from R&D Systems (Quantikine HS ELISA Kit; Minneapolis, MN). Serum erythropoietin levels were determined with a commercially available ELISA kit (DRG Instruments, Marburg, Germany).

**Animals**

Female Lewis rats (Charles River Laboratories, Sulzfeld, Germany) were kept on a standard rodent diet (180 mg Fe/kg, C1000 from Altromin, Lage, Germany) until they reached an age of 8 to 10 weeks. The animals had free access to food and water and were kept according to institutional and governmental guidelines in the animal quarters of the Medical University of Innsbruck with a 12-hour light-dark cycle and an average temperature of 20°C plus or minus 1°C. Design of the animal experiments was approved by the Austrian Federal Ministry of Science and Research (BMWF-66.011/0146-11/08/2008 and BMWF-66.011/0074-11/08/2008).

Rats were inoculated on day 0 with an intraperitoneal injection of PG-APS (Lee Laboratories, Grayson, GA) suspended in 0.85% saline with a total dose of 15 µg rhamnose/g body weight. Carrier-immunized control rats received intraperitoneal injections of sterile 0.85% saline.

One group of rats was phlebotomized, starting 1 week before death; 1.8 mL blood was taken daily for 5 consecutive days. Sera were stored at −80°C for further analysis.

Three weeks after PG-APS administration, all rats were killed and tissue was harvested for RNA and protein extraction, immunohistochemistry, and in vitro stimulation assays. Blood was collected by puncture of the tail veins, and complete blood counts were performed on a Beckman Coulter instrument (Fullerton, CA). Rat serum EPO levels were determined using an ELISA kit (R&D Systems) with a minimum detection limit of 22.5 pg/mL.

**RNA preparation from tissue, reverse transcription, and TaqMan real-time PCR**

Total RNA preparation from nitrogen-frozen tissue and rat urine, reverse transcription of 4 µg RNA, and TaqMan real-time polymerase chain reaction (PCR) were performed as previously described.20

The following primers and TaqMan probes were used: (1) human: ferroportin: 5’-TGACAGGGGCGAGA-3’ (600 nM), 5’-AGCCAGCAGGATGACGATGTGCGCA-3’ (600 nM); FAM-CACAACCGCAGAGAGATGGCTGTG-BHQ1 (200 nM); DMF-lirze: 5’-GTGGTCAAGCCTGGTCTATCGTAGTTTAC-3’ (600 nM), 5’-GCCCTTGAAGATCTTACCAGT-3’ (600 nM), FAM-TGTTCCTACTTGGGATGATGGTTCAG-BHQ1 (200 nM); (2) rat: ferroportin: 5’-TGTCAGCTGGTCTATCAGTG-3’ (600 nM), 5’-AGATGAGGTCTGTTTCC-3’ (600 nM), 5’-AGTTATGCGTTCGGTGTTAC-3’ (600 nM), FAM-CGACTTAAAGTTCCGAGTGTTTCTCGT-BHQ1 (200 nM); DMT-lirze: 5’-GCCCTTGTTCCTTGGATGTG-3’ (600 nM), 5’-ATTCCTGCGGCGCTGAGC-3’ (600 nM), FAM-TGAAGGAGAAGTGGCTGAC-3’ (600 nM), FAM-CGACGGCGAGAGAGATGGCTGTTTAC-3’ (600 nM), FAM-TGAAGGAGAAGTGGCTGAC-3’ (600 nM), FAM-CGACGGCGAGAGAGATGGCTGTTTAC-3’ (500 nM); bGus: 5’-ATACCTGCGAGAAGTGGCTGAC-3’ (200 nM), 5’-GCCCTTGTTCCTTGGATGTG-3’ (600 nM), FAM-CGACGGCGAGAGAGATGGCTGTTTAC-3’ (500 nM).

**Western blotting**

Protein extracts were prepared from nitrogen-frozen tissue, and Western blotting was performed as previously described.21 Anti-TfR1 antibody (0.5 µg/mL; Zymed Laboratories, South San Francisco, CA), antiferritin antibody (2 µg/mL; Dako North America, Carpinteria, CA), anti-rat ferroportin antibody,21 anti-rat DMT-1 antibody,22 or antiactin (2 µg/mL; Sigma Chemie, Deisenhofen, Germany) was used as described.20

**Immunohistochemistry**

Formalin-fixed, paraffin-embedded tissue specimens were used. Immunohistochemistry was performed exactly as described previously.22

**Quantitative measurement of duodenal iron uptake in vivo**

For radioactive iron uptake assays, control rats, rats with ACD, and rats with ACD with true iron deficiency were gavaged with 20 nmol 59Feirc
citrate (specific activity > 3 mCi/mg 59Fe; PerkinElmer Life and Analytical Sciences, Waltham, MA) in 100 μL N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid buffer using a gastric tube. All rats were fasted 24 hours before initiation of the oral iron uptake assay. At 30, 60, and 90 minutes after oral iron administration, blood was collected by tail vein puncture. After the last blood sampling, animals were killed. Radioactive iron content in serum was measured using a γ-counter. Although this method allows the performance of a time course experiment in a single animal, a limitation of this method may arise from the fact that the amount of iron being absorbed can be underestimated because the metal is readily shifted to the liver.

**Quantification of macrophage iron transport**

For macrophage iron uptake and release studies, resident peritoneal macrophages were harvested from control and anemic rats. A total of 0.5 × 10^6 peritoneal macrophages were seeded in 12-well dishes in 750 μL RPMI containing 5% fetal calf serum (endotoxin free), 2 mM L-glutamine, 100 U/mL penicillin, 0.1 mg/mL streptomycin, and 10 mM N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid (Sigma Chemie). Macrophages were allowed to adhere for 20 minutes and then washed extensively to remove nonadherent cells. After a resting period of 2 to 4 hours, cells were washed 3 times with serum-free RPMI containing 25 mM N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid and then incubated therein. Acquisition of transferrin-bound iron (TBI) and nontransferrin-bound iron (NTBI) as well as cellular iron efflux by isolated rat macrophages were determined exactly as described.22 After 4 hours of iron uptake, iron uptake was quantified. For release, at first, cells were loaded with iron for 4 hours. Iron release was quantified after additional 4 hours.

**Serum hepcidin determination**

Determination of hepcidin in human and rat serum was performed as previously detailed24 with slight modifications. In brief, serum samples were precipitated by mixing 50 μL acetonitrile with 25 μL serum. The samples were then centrifuged at 4000g for 10 minutes at 5°C. Thereafter, a 200-μL aliquot of internal standard solution was added to the supernatant. Alternatively, serum samples were processed by acid dissociation by mixing 50 μL serum with 200 μL 0.2% formic acid containing internal standard. The supernatant from the acetonitrile precipitation or the formic acid dissociation solutions were then extracted, reconstituted, and analyzed as previously described.24 A Finnigan TSQ Quantum Ultra (Thermo Electron, Waltham, MA) electrospray mass spectrometer was used for the detection of rat hepcidin and the internal standard. The most abundant charge state of each analyte was subjected to collisional induced dissociation using compressed zero-grade Argon (99.998%; Linde Gas, Wilmington, DE). The most abundant fragment ion from each protonated precursor ion then was selected for selected reaction monitoring.

**Data analysis**

Statistical analysis was carried out using Statistics Package for the Social Science software package, version 15.1 (SAS Institute, Chicago, IL). Calculations for statistical differences between the various groups were carried out by analysis of variance technique and Bonferroni correction for multiple tests.

**Results**

We first investigated the effects of a chronic inflammation, which was induced on PG-APS administration on hemato logic parameters in rats. Injection of 15 μg/g PG-APS into rats resulted in the development of anemia within 2 weeks, and the anemia persisted for at least 3 months (not shown). This anemia displayed the classic features of ACD in humans, namely, mild to moderate normochromic and normocytic anemia with hypoferremia and inflammation. Some control rats underwent phlebotomy to induce IDA. Phlebotomy was also performed in some inflammatory rats to induce true iron deficiency, which then served as a model for ACD in association with chronic bleeding episodes (ACD/IDA). No significant difference in white blood cell count was found between ACD and ACD/IDA rats, although white blood cell counts were elevated compared with control rats (P < .001). Serum iron levels were significantly reduced in phlebotomized (P < .005), ACD (P < .001), and ACD/IDA (P < .001) rats compared with control rats. There was a trend toward lower serum iron levels in ACD/IDA rats compared with ACD rats (Table 1).

Because anemia results in increased formation of EPO, we studied differences in EPO expression between the different groups. Rats with IDA alone had significantly higher EPO levels than controls (P < .001) but significantly lower EPO levels than rats with ACD/IDA (P < .05; Table 1). EPO levels were almost undetectable in control and ACD rats, which may be the result of the limited sensitivity of the EPO rat ELISA already reported in the manufacturer’s instructions.

Because no suitable animal model for prolonged chronic inflammatory anemia was available so far, we next studied alterations in body iron homeostasis occurring in ACD with/without true iron deficiency. Therefore, we analyzed the expression of critical iron metabolism genes in the duodenum, spleen, and liver because these are the central organs for iron regulation (liver), iron retention (spleen), and iron absorption (duodenum). In the liver, we found a significant increase of DMT-1 mRNA levels and protein expression in ACD and ACD/IDA rats compared with control and IDA animals (P = .001; Figures 1Aii, 2A). Although hepatic TIR-1 mRNA expression was not different (Figure 1Ai) between the 4 groups, TIR-1 protein levels were increased in ACD and/or IDA animals compared with controls (Figure 2A). Ferroportin mRNA and protein levels showed no significant changes in the liver between the 4 groups (Figures 1Aii, 2A). Notably, we observed a reduced hepatic ferritin protein expression in ACD rats (Figure 2A).

---

**Table 1. Selected baseline parameters of control, IDA, ACD, and ACD/IDA rats**

<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th>IDA</th>
<th>ACD</th>
<th>ACD/IDA</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>6</td>
<td>7</td>
<td>7</td>
<td>6</td>
</tr>
<tr>
<td>Hb, g/dL</td>
<td>15.1 ± 0.23</td>
<td>12.7 ± 0.8*</td>
<td>10.4 ± 2.2†‡</td>
<td>8.7 ± 1.6†‡</td>
</tr>
<tr>
<td>WBC, &gt;10^9/μL</td>
<td>6.0 ± 0.6</td>
<td>6.8 ± 0.7</td>
<td>30.0 ± 15.0*</td>
<td>35.0 ± 16.0†</td>
</tr>
<tr>
<td>Fe, μmol/L</td>
<td>266.9 ± 57.1</td>
<td>145.7 ± 70.5*</td>
<td>68.4 ± 48.6†</td>
<td>38.2 ± 24.4†‡</td>
</tr>
<tr>
<td>EPO, pg/mL</td>
<td>0.0 ± 0.0</td>
<td>81.7 ± 104.3†</td>
<td>0.0 ± 0.0</td>
<td>321.6 ± 285.1†‡</td>
</tr>
</tbody>
</table>

Calculations for statistical differences between the various groups were carried out by Anova analysis and Bonferroni correction for multiple tests. Data are shown as means ± SD in each group.

*P < .05 when comparing control animals with IDA, ACD or ACD/IDA, respectively.
†P < .001 when comparing control animals with IDA, ACD or ACD/IDA, respectively.
‡P < .05 when comparing IDA with ACD or ACD/IDA, respectively.
§P < .05 when comparing ACD with ACD/IDA.
Figure 1. Changes of iron metabolism gene expression in liver, spleen, and duodenum between the different anemia groups. Rats were inoculated on day 0 with an intraperitoneal injection of PG-APS to induce anemia of chronic disease (ACD) or left untreated (control). One group of PG-APS-treated and control rats was phlebotomized, starting 1 week before death, to create a combination of ACD and iron deficiency anemia (ACD/IDA) or IDA alone, respectively. Nitrogen snap-frozen tissue was subjected to RNA preparation, followed by reverse transcription and quantitative TaqMan PCR. In the liver (A), spleen (B), and duodenum (C), the TfR-1 (i), ferroportin (ii), and DMT-1 (iii) mRNA expression was determined by quantitative RT-PCR and normalized to the mRNA expression level of the housekeeping gene β-glucuronidase (Gusb). Data are depicted as lower quartile, median, and upper quartile (boxes) and minimum/maximum ranges (whiskers). Calculations for statistical differences between the various groups were carried out by analysis of variance technique and Bonferroni correction for multiple tests.
Spleen TIR mRNA expression was significantly elevated in the ACD/IDA group compared with the control and IDA group, respectively \((P < .05)\). TIR-1 protein expression in the spleen paralleled the changes observed in the liver (Figures 1Bi, 2B). In contrast, ferroportin mRNA and protein expression was reduced in association with ACD compared with controls \((P < .001; \text{Figure } 1\text{Bii})\). Although ferroportin mRNA levels were not significantly different, ACD/IDA rats had higher ferroportin protein expression than rats with ACD alone (Figure 2B). Accordingly, we found increased ferritin protein levels in the spleen of ACD rats, whereas they were low in ACD/IDA rats (Figure 2B).

In the duodenum, we observed increased TIR-1 mRNA levels in phlebotomized animals (Figure 1Ci). We also found higher DMT-1 mRNA levels in IDA and ACD/IDA rats compared with control rats \((P < .05; \text{Figure } 1\text{Ci})\). Accordingly, ferroportin mRNA expression was significantly higher in IDA \((P < .005)\) and ACD/IDA \((P < .05)\) animals than in controls or ACD rats (Figure 1Ci). These alterations were paralleled by corresponding changes in ferroportin protein expression as determined by immunohistochemistry (Figure 2C).

Because we observed striking differences in the duodenal and splenic expression of ferroportin between ACD and IDA animals, we next studied hepatic hepcidin mRNA expression and serum hepcidin levels in the 4 different groups of animals (Figure 3). We found liver hepcidin mRNA expression \((P < .001)\) and serum hepcidin levels \((P < .001)\) to be significantly higher in ACD rats than in control animals, whereas IDA rats without inflammation presented with decreased hepatic hepcidin mRNA expression \((P < .001)\) and serum concentrations \((P < .05)\) compared with controls. Although liver hepcidin mRNA and serum hepcidin levels were not statistical different between ACD/IDA and IDA rats, they were significantly lower than those observed in ACD rats \((P < .001); \text{Figure } 3\)\).

Based on these results, we then determined whether the different expression of hepcidin and iron transporters between the 4 animal groups would impact on intestinal iron absorption and/or iron recirculation form macrophages. When studying iron transport in primary peritoneal macrophages from ACD rats, we observed an increased uptake of TBI \((P = .001; \text{Figure } 4\text{A})\) and NTBI \((P < .001; \text{Figure } 4\text{B})\) compared with controls. Cellular iron incorporation was further enhanced in macrophages from ACD/IDA rats \((P < .001; \text{Figure } 4\text{A}, \text{B})\), whereas no difference was observed between control and IDA animals (Figure 4AB). In contrast, iron release from macrophages of ACD rats was significantly decreased compared with controls \((P = .001)\), whereas macrophage iron release from ACD/IDA macrophages was significantly higher than in ACD macrophages \((P < .001; \text{Figure } 4\text{C})\).

When investigating duodenal absorption of radioactive iron, we found that ACD rats took up significantly less orally administered iron than controls at 30, 60, and 90 minutes after exposure \((P < .05; \text{Figure } 5\text{A})\). In contrast, rats with ACD/IDA absorbed duodenal iron significantly better than ACD rats \((P < .05; \text{Figure } 5B)\). These combined observations perfectly fit to the described alterations of ferroportin expression in the spleen and duodenum (Figure 2B,C).

To determine whether the results obtained in rats also apply to humans, we studied serum samples and duodenal biopsies from subjects with IDA, ACD, or ACD/IDA. As shown in Figure 6A, all
anemic patients had lower hemoglobin levels than control subjects. In addition, ACD/IDA patients had lower mean corpuscular hemoglobin \((P < .001;\) Figure 6B) and lower mean corpuscular volume \((P < .05;\) Table S1, available on the Blood website; see the Supplemental Materials link at the top of the online article) than the ACD group. As the log ferritin/sTfR ratio was used to categorize patients as having either ACD or ACD/IDA, this ratio is not shown. As expected, serum ferritin levels were significantly elevated in ACD patients compared with controls \((P < .001)\) and significantly lower in ACD/IDA patients than in ACD patients \((P < .001)\). Serum EPO levels were significantly elevated in IDA \((P < .001)\) and ACD/IDA \((P < .001)\) patients but not in ACD patients compared with controls \((P < .001)\). As expected, IL-6 and C-reactive protein levels were significantly higher in ACD \((P < .001)\) and ACD/IDA \((P = .001)\) patients than in controls, whereas no difference was found between ACD and ACD/IDA patients \((P < .001)\) compared with controls. Importantly, ACD subjects had significantly higher serum hepcidin levels than ACD/IDA patients \((P < .001)\), and the latter group was not different from IDA patients \((P < .001)\).

We found low hepcidin levels in IDA patients \((P < .005)\) but increased hepcidin concentrations in ACD subjects \((P < .001)\) compared with controls. Importantly, ACD subjects had significantly higher serum hepcidin levels than ACD/IDA patients \((P < .001)\), and the latter group was not different from IDA patients \((P < .001)\).

When investigating duodenal biopsies from patients, we observed significantly higher ferroportin mRNA expression in ACD \((P < .005)\) and ACD/IDA \((P < .05)\) patients than in control and ACD patients, respectively \((P < .001)\). This was paralleled by corresponding changes in ferroportin protein expression \((P < .001)\). Duodenal ferroportin expression was inversely related to...
Figure 5. Alterations of duodenal iron uptake between ACD and ACD/IDA rats in vivo. For radioactive iron uptake assays, control rats (open boxes), rats with ACD (light gray boxes), and rats with ACD with true iron deficiency (ACD/IDA; dark gray boxes) were orally fed with $^{59}$Fe citrate using a gastric tube. At 30, 60, and 90 minutes after oral iron administration, blood was collected by tail vein puncture. Radioactive iron content in serum was measured using a $\gamma$-counter. Figure 1 contains details on graphs and statistics.

Figure 6. Selected baseline parameters of control, IDA, ACD, and ACD/IDA patients. Laboratory parameters, including hemoglobin, mean corpuscular hemoglobin, serum ferritin, serum erythropoietin, serum IL-6, and serum hepcidin, are shown. Figure 1 contains details on graphs and statistics.
serum hepcidin and ferritin levels, but not to IL-6 serum concentrations (Figures 6E,F, 7C). Thus, the human data very closely resembled the observations made in rats.

**Discussion**

ACD is frequently found in patients with diseases associated with chronic immune activation. ACD is associated with reduced erythrocyte life span, impaired erythroid progenitor proliferation, and impaired biologic activity of erythropoietin. In addition, cytokine and hepcidin-driven iron retention by macrophages leads to functional iron deficiency, which contributes to anemia. A significant proportion of patients with ACD have concurrent blood loss, leading to true iron deficiency (ACD/IDA). Until now, little has been known concerning potential differences in the control of iron homeostasis between persons with ACD versus those with ACD/IDA. It is important to distinguish between ACD and ACD/IDA to appropriately guide therapeutic regimens, especially in respect to iron repletion strategies.

We used a rat model of inflammation-associated chronic anemia to investigate the regulation of body iron homeostasis in ACD. We observed increased expression of the iron storage protein ferritin in the spleen but not in the liver, a finding in accordance with previous data demonstrating divergent ferroportin regulation by hepcidin in duodenum and liver. Tissue-specific differences in ferritin levels were paralleled by decreased expression of ferroportin in the spleen but not in the liver, a finding in accordance with previous data demonstrating divergent ferroportin regulation by hepcidin in duodenum and liver. Tissue-specific differences in ferritin levels were paralleled by decreased expression of ferroportin in the spleen but not in the liver, a finding in accordance with previous data demonstrating divergent ferroportin regulation by hepcidin in duodenum and liver.

Figure 7. Expression profiles of iron transporter in human duodenal biopsies from control, IDA, ACD, and ACD/IDA patients. Duodenal biopsies were snap-frozen in liquid nitrogen and RNA was prepared, followed by reverse transcription and quantitative TaqMan PCR for ferroportin (A) and DMT-1 (B) mRNA expression. Values were normalized to the mRNA expression levels of the housekeeping gene β-actin. (C) Duodenal biopsies of control (i), IDA (ii), ACD (iii), and ACD/IDA (iv) patients were subjected to immunohistochemistry using an affinity-purified antiferroportin antibody. A representative slide for each parameter measured is shown. Indicates the basolateral ferroportin expression. The images were captured by an Olympus BX51 microscope (Plan FL40×/0.75; Olympus) using a ProgResC12 plus camera (Jenoptik) and ProgResCapturePro2.5 software. In addition, the corresponding hemoglobin, serum IL-6, serum ferritin concentrations, and serum hepcidin levels are shown. n.d. indicates not detectable. Figure 1 contains details on graphs and statistics.
Studies on the regulation of iron absorption in ACD and ACD/IDA produced inconsistent and contrasting results so far. Reduced duodenal iron uptake was observed in rheumatoid arthritis patients with ACD, which was paralleled by iron accumulation in the bone marrow. However, these findings were not confirmed by a similar study. Contrasting observations may relate to differences in the definition of "true" vs "functional" iron deficiency and various iron preparation and dosing regimen used in iron uptake studies. Chaston et al reported that synthetic hepcidin did not reduce ferroportin expression in mouse duodenum or in CaCo2 cells, at least acutely, but hepcidin strongly reduced ferroportin expression in macrophages. Moreover, a recent study suggested that hepcidin may affect only apical but not basolateral transport in intestinal cells. However, hepcidin formation has been shown to inversely correlate with the expression of duodenal ferroportin and to affect iron absorption, which is in accordance with the data provided herein, both in humans and in rats. Our results further agree with recently published data indicating changes of liver hepcidin mRNA expression by phlebotomy in a mouse model of critical illness associated anemia.

This leads to the question on the signals controlling hepcidin expression and body iron homeostasis in ACD versus ACD/IDA. While this paper was under revision, a study on anemia in pediatric refugees was published that found an association of decreased urinary hepcidin levels with hemoglobin, ferritin, and serum iron but not to IL-6 concentrations.

This is in accordance with our observed lack of differences in circulating IL-6 levels between ACD and ACD/IDA subjects (low serum hepcidin), suggesting that the erythroid demand for iron is a more powerful regulator of hepcidin expression than inflammation-induced hepcidin formation. However, as a limitation of this study, we were not able to distinguish between the effects of a putative erythropoietic stimulation and the effects of iron deficiency on hepcidin expression when analyzing the combined effects of bleeding and inflammation, although EPO levels were significantly higher in ACD/IDA compared with ACD subjects. EPO levels were also elevated in mice with IDA, whereas EPO concentrations did not correlate with hemoglobin concentrations during inflammation. In this latter setting, serum EPO levels may be thus a combined reflection of inflammation, iron deficiency, and erythropoiesis-driven regulatory effects. The rat model described here would be a valuable tool to characterize the regulatory effects of EPO and recently identified erythropoietin driven regulators of iron homeostasis, such as GAS6, GDF-15, or Tmprss6, in ACD and ACD/IDA.

Because circulating hepcidin levels were clearly different between ACD and ACD/IDA subjects, one might suggest that the determination of hepcidin in serum might be a valuable diagnostic tool to distinguish between ACD and ACD/IDA. As ferritin in the setting of inflammation does not accurately reflect iron stores, this has led others to use the ratio of sTfR/log ferritin, but this measurement has not gained acceptance and has several limitations. Bone marrow aspiration stained with Prussian blue is considered the most reliable method of determining bone marrow iron stores, but this represents an invasive method. In contrast, serum hepcidin levels are an easy to obtain parameter and reflect the needs of iron for erythropoiesis in the setting of inflammation. Differentiating between ACD and ACD/IDA is clinically important because iron supplementation to patients with ACD on the basis of infections and malignancies may have detrimental effects resulting from the growth-promoting effect of iron on tumor cells and microorganisms and the negative effect of iron on innate immune functions.

In contrast, patients with ACD/IDA require iron for basic metabolic function and erythropoiesis. However, the longstanding effects of iron supplementation on the course of diseases underlying ACD have not been established in prospective clinical trials. Our results suggest that patients with ACD/IDA would respond to treatment with oral iron supplementation, as hepcidin levels are low and duodenal ferroportin expression and duodenal iron absorption are increased. Moreover, hepcidin determination may be useful to monitor the therapeutic success of iron supplementation therapies, even before an increase of hemoglobin levels can be observed. Hepcidin levels could thus aid in estimating the needs of iron for erythropoiesis in subjects with other forms of anemia, for example, in dialysis patients.

Acknowledgments

This study was supported by the Austrian Fonds zur Förderung der Wissenschaftlichen Forschung (grant P-19964; G.W.), the European Union project Euroiron1 (G.W.), the Austrian National Bank Research Fund (P-125558; I.T.), the Medical University of Innsbruck Young Investigator Fund (2007-416; I.T.), and the Medizinischer Forschungsfonds Tirol (no. 188; I.T., M.T.).

Authorship

Contribution: I.T. and G.W. designed the research, controlled and analyzed the data, and wrote the paper; I.T., E.A., M.T., M.N., M.S., A.S., T.E., D.R.W., A.T.M., V.J.W., E.W., C.D., and G.W. performed the research and examined the patients; and all authors checked the final version.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Guenter Weiss, Medical University, Department of Internal Medicine I, Clinical Immunology and Infectious Diseases, Anichstr 35, A-6020 Innsbruck, Austria; e-mail: guenter.weiss@i-med.ac.at.

References

9. Punnonen K, Irjala K, Rajamaki A. Serum transferrin receptor and its ratio to serum ferritin in the...
diagnosis of iron deficiency. Blood. 1997;89:
1052-1057.

encoding the iron regulatory peptide hepcidin is
regulated by anemia, hypoxia, and inflammation.

Regulatory defects in liver and intestine implicate
abnormal hepcidin and Cybrd1 expression in
mouse hemochromatosis. Nat Genet. 2003;34:
102-107.

regulates cellular iron efflux by binding to ferro-
portin and inducing its internalization. Science.
2004;306:2090-2093.

13. Fleming RE. Iron and inflammation: cross-talk
2008;86:491-494.

14. Weinstein DA, Roy CN, Fleming MD, Loda MF,
Wolfsdorf J, Andrews NC. Inappropriate expres-
sion of hepcidin is associated with iron refractory
anemia: implications for the anemia of chronic

15. Kemna E, Pickkers P, Nemeth E, van der Hoeven
H, Swinkels D. Time-course analysis of hepcidin,
serum iron, and plasma cytokine levels in hu-

mation of hepcidin induces iron retention in hu-
mans mammals injected with LPS. Blood. 2005;106:
1864-1866.

2008;112:4292-4297.

18. Constanze M, Wang D, Raymond VA, Blodeau M,
Santos MM. Repression of repulsive guidance
molecule C during inflammation is independent of
Hfe and involves tumor necrosis factor-alpha.

19. Cromartie WJ, Craddock JG, Schwab JH,
Anderle SK, Yang CH. Arthritis in rats after sys-
temic injection of streptococcal cells or cell walls.
Anderle SK, Yang CH. Arthritis in rats after sys-
temic injection of streptococcal cells or cell walls.

20. Knutson M, Wessling-Resnick M. Iron metabo-
lism in the reticuloendothelial system. Crit Rev

Ca2+ channel blockers reverse iron overload by
a new mechanism via divalent metal trans-

the regulation of body iron homeostasis in re-
sponse to experimental iron overload. J Hepatol.

23. Nairz M, Theurl I, Ludwigz S, et al. The co-
ordinated regulation of iron homeostasis in mu-
rine iron metabolism limits the availability of iron for
intracellular Salmonella typhimurium. Cell Micro-
biof. 2007;8:2126-2140.

24. Murphy AT, Witter DR, Luan P, Wroblewski VJ.
Quantitation of hepcidin from human and mouse
mice using liquid chromatography tandem mass

25. Theurl I, Mattie V, Seifert M, Mariani M, Marth C,
Weiss G. Dysregulated monocyte iron homeosta-
sis and erythropoiesis formation in patients with
anemia of chronic disease. Blood. 2006;107:
4142-4148.

26. Ganz T. Hepcidin: a regulator of intestinal iron
absorption and iron recycling by macrophages.

27. Thomas C, Thomas L. Anemia of chronic dis-
 ease: pathophysiology and laboratory diagnosis.

pression of hemochromatosis genes in two mouse
strains after phlebotomy and iron over-

29. Ludwigsz S, Alpern E, Theurl I, Weiss G. Cytokine-
mediated regulation of iron transport in human

30. Recalcati S, Pometta R, Levi S, Conte D, Cairo
G. Response of monocyte iron regulatory protein
to inflammation: abnormal behavior in ge-
etic hemochromatosis. Blood. 1998;91:2565-
2572.


32. Knutson M, Westling-Resnick M. Iron metabo-
lism in the reticuloendothelial system. Crit Rev

33. Yang F, Liu XB, Quinones M, Melby PC, Ghio A,
Hail DJ. Regulation of reticuloendothelial iron
transporter MTP1 (Slc11a3) by inflammation. J Biol
Chem. 2002;277:39786-39791.

iron deficiency anemia in transgenic mice ex-
pressing liver hepcidin. Proc Natl Acad Sci U S A.
2002;99:4596-4601.

35. Weber J, Wierke JM, Julius HH, Marx J. De-
creased iron absorption in patients with active
rheumatoid arthritis, with and without iron defi-

36. Raja KB, Duane P, Snape SD, Simpson RJ,
Papasavvas G, Peters TJ. In vitro duodenal iron
uptake and serum and mucosal iron protein lev-
els, with special reference to rheumatoid arthritis.

37. De Pont T, Chung B, Mascarenhas M, et al. Ev-
dence for differential effects of hepcidin in macro-
phages and intestinal epithelial cells. Gut. 2008;
57:374-382.

38. Mena NP, Espana Z, Tapia V, Valdes P, Nunez
MT. Hepcidin inhibits apical iron uptake in intesti-
nal cells. Am J Physiol Gastrointest Liver Physiol.
2008;294:G192-G198.

din expression inversely correlates with the ex-
pression of duodenal iron transporters and iron
absorption in rats. Gastroenterology. 2002;123:
835-844.

of hepcidin on intestinal iron absorption in mice.
Blood. 2004;103:3940-3944.

41. Lasocki S, Millot S, Andreu V, et al. Phelbitomytes
or erythropoietin injections allow mobilization of
iron stores in a mouse model mimicking intensive

into the relationships between hepcidin, anemia,
infections and inflammatory cytokines in pediatric
2008;3:e4030.

depression increases erythropoietin production in
vitro, in normal subjects and patients with mali-

44. Du X, She E, Gelbart T, et al. The serine protease
TMRPSS6 is required to sense iron deficiency.

45. Angelillo-Scherrer A, Burnier L, Lambrechts D, et
al. Role of Gas1 in erythropoiesis and anemia in

46. Tanno T, Bhanu NV, Oneal PA, et al. High levels
of GDF15 in thalassemia suppress expression of
the iron regulatory protein hepcidin. Nat Med.

47. Silvestri L, Pagani A, Nai A, De Domenico I,
Kaplan J, Camaschella C. The serine protease
matrkapase-2 (TMPRSS6) inhibits hepcidin activa-
tion by cleaving membrane hemoglobin. Cell
Metab. 2006;8:502-511.

48. Weinberg ED. The role of iron in cancer. Eur J

49. Gordeuk VR, Ojooji G, Schneider MF, et al. The
association of serum ferritin and transferrin re-
ceptor concentrations with mortality in women
with human immunodeficiency virus infection.
Haematologica. 2006;91:739-743.

50. Goodnough LT, Skikne B, Brugnara C. Erythro-
poietin, iron, and erythropoiesis. Blood. 2000;96:
823-833.